DLX6 and colorectal carcinoma: Last, although we found that the aberrant methylation of DLX6-AS1 might serve as a potential biomarker for CRC progression and prognosis, external validation with larger and diverse study populations is still required to further confirm the clinical value of DLX6-AS1 methylation in CRC.